$61.44
0.621.02%
At Close: -
$61.44
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
ANI Pharmaceuticals
ANIPNASDAQ
want to know what
the Bulls & Bears Say?
ANI Pharmaceuticals (NASDAQ:ANIP) Stock, Analyst Ratings, Price Targets, Forecasts
ANI Pharmaceuticals Inc has a consensus price target of $60 based on the ratings of 27 analysis. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Guggenheim on June 26, 2024, May 13, 2024, and April 23, 2024, respectively. With an average price target of $86 between HC Wainwright & Co., HC Wainwright & Co., and Guggenheim, there's an implied 39.97% upside for ANI Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Guggenheim
Capital One
Truist Securities
Raymond James
1calculated from analyst ratings
Analyst Ratings for ANI Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/26/2024 | Buy Now | 52.99% | HC Wainwright & Co. | Oren Livnat | $87 → $94 | Maintains | Buy | Get Alert |
| 05/13/2024 | Buy Now | 41.6% | HC Wainwright & Co. | Oren Livnat | $83 → $87 | Maintains | Buy | Get Alert |
| 04/23/2024 | Buy Now | 25.33% | Guggenheim | Vamil Divan | → $77 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | Buy Now | — | Capital One | Timothy Chiang | — | Initiates | → Overweight | Get Alert |
| 03/05/2024 | Buy Now | 25.33% | Guggenheim | Vamil Divan | $70 → $77 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 35.09% | HC Wainwright & Co. | Oren Livnat | $73 → $83 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | 30.21% | Truist Securities | Gregory Fraser | $72 → $80 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 17.19% | Truist Securities | Gregory Fraser | $70 → $72 | Maintains | Buy | Get Alert |
| 10/19/2023 | Buy Now | 17.19% | Guggenheim | Vamil Divan | → $72 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 17.19% | Guggenheim | Vamil Divan | → $72 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2023 | Buy Now | 18.82% | HC Wainwright & Co. | Oren Livnat | $60 → $73 | Maintains | Buy | Get Alert |
| 08/21/2023 | Buy Now | 13.93% | Truist Securities | Gregory Fraser | → $70 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 17.19% | Guggenheim | Vamil Divan | $62 → $72 | Maintains | Buy | Get Alert |
| 07/27/2023 | Buy Now | 0.91% | Guggenheim | Vamil Divan | $59 → $62 | Maintains | Buy | Get Alert |
| 07/21/2023 | Buy Now | -2.34% | Truist Securities | Gregory Fraser | $52 → $60 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | -3.97% | Guggenheim | Vamil Divan | $55 → $59 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | -15.36% | Truist Securities | Gregory Fraser | $50 → $52 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | -20.25% | Raymond James | Elliot Wilbur | $48 → $49 | Maintains | Outperform | Get Alert |
| 05/09/2023 | Buy Now | -2.34% | HC Wainwright & Co. | Oren Livnat | $53 → $60 | Maintains | Buy | Get Alert |
| 03/13/2023 | Buy Now | -13.74% | HC Wainwright & Co. | Oren Livnat | $50 → $53 | Maintains | Buy | Get Alert |
| 03/01/2023 | Buy Now | -10.48% | Guggenheim | Vamil Divan | → $55 | Initiates | → Buy | Get Alert |
| 02/21/2023 | Buy Now | -18.62% | HC Wainwright & Co. | Oren Livnat | → $50 | Reiterates | → Buy | Get Alert |
| 09/07/2022 | Buy Now | -18.62% | HC Wainwright & Co. | Oren Livnat | → $50 | Initiates | → Buy | Get Alert |
| 08/09/2022 | Buy Now | -21.87% | Raymond James | Elliot Wilbur | $47 → $48 | Maintains | Outperform | Get Alert |
| 03/16/2022 | Buy Now | -23.5% | Raymond James | Elliot Wilbur | $65 → $47 | Maintains | Outperform | Get Alert |
| 11/02/2021 | Buy Now | 5.79% | Raymond James | Elliot Wilbur | — | Maintains | Outperform | Get Alert |
| 11/02/2021 | Buy Now | 13.93% | Truist Securities | Gregory Fraser | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for ANI Pharmaceuticals (ANIP) stock?
The latest price target for ANI Pharmaceuticals (NASDAQ:ANIP) was reported by HC Wainwright & Co. on June 26, 2024. The analyst firm set a price target for $94.00 expecting ANIP to rise to within 12 months (a possible 52.99% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ANI Pharmaceuticals (ANIP)?
The latest analyst rating for ANI Pharmaceuticals (NASDAQ:ANIP) was provided by HC Wainwright & Co., and ANI Pharmaceuticals maintained their buy rating.
When was the last upgrade for ANI Pharmaceuticals (ANIP)?
There is no last upgrade for ANI Pharmaceuticals
When was the last downgrade for ANI Pharmaceuticals (ANIP)?
There is no last downgrade for ANI Pharmaceuticals.
When is the next analyst rating going to be posted or updated for ANI Pharmaceuticals (ANIP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ANI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ANI Pharmaceuticals was filed on June 26, 2024 so you should expect the next rating to be made available sometime around June 26, 2025.
Is the Analyst Rating ANI Pharmaceuticals (ANIP) correct?
While ratings are subjective and will change, the latest ANI Pharmaceuticals (ANIP) rating was a maintained with a price target of $87.00 to $94.00. The current price ANI Pharmaceuticals (ANIP) is trading at is $61.44, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.